WO2010013768A1 - チアゾリジンジオン化合物の結晶及びその製造方法 - Google Patents

チアゾリジンジオン化合物の結晶及びその製造方法 Download PDF

Info

Publication number
WO2010013768A1
WO2010013768A1 PCT/JP2009/063556 JP2009063556W WO2010013768A1 WO 2010013768 A1 WO2010013768 A1 WO 2010013768A1 JP 2009063556 W JP2009063556 W JP 2009063556W WO 2010013768 A1 WO2010013768 A1 WO 2010013768A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal
production
compound
thiazolidinedione compound
disclosed
Prior art date
Application number
PCT/JP2009/063556
Other languages
English (en)
French (fr)
Inventor
久喜 梶野
豊 池内
英治 沼上
悟 二瓶
Original Assignee
第一三共株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共株式会社 filed Critical 第一三共株式会社
Priority to US13/056,648 priority Critical patent/US20110124692A1/en
Priority to EP09803010A priority patent/EP2305673A4/en
Priority to JP2010522748A priority patent/JPWO2010013768A1/ja
Publication of WO2010013768A1 publication Critical patent/WO2010013768A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤、抗癌医薬組成物の製造原体として有用な、チアゾリジンジオン化合物の結晶を提供する。下記一般式（I）： で表される、５－(４－{[６－(４－アミノ－３,５－ジメチルフェノキシ)－１－メチル－１－Ｈ－ベンツイミダゾール－２－イル]メトキシ}ベンジル)－１,３－チアゾリジン－２,４－ジオン、およびその２塩酸塩の水和物結晶。
PCT/JP2009/063556 2008-07-31 2009-07-30 チアゾリジンジオン化合物の結晶及びその製造方法 WO2010013768A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/056,648 US20110124692A1 (en) 2008-07-31 2009-07-30 Crystalline forms of thiazolidinedione compound and its manufacturing method
EP09803010A EP2305673A4 (en) 2008-07-31 2009-07-30 CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
JP2010522748A JPWO2010013768A1 (ja) 2008-07-31 2009-07-30 チアゾリジンジオン化合物の結晶及びその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-197306 2008-07-31
JP2008197306 2008-07-31

Publications (1)

Publication Number Publication Date
WO2010013768A1 true WO2010013768A1 (ja) 2010-02-04

Family

ID=41610467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/063556 WO2010013768A1 (ja) 2008-07-31 2009-07-30 チアゾリジンジオン化合物の結晶及びその製造方法

Country Status (5)

Country Link
US (1) US20110124692A1 (ja)
EP (1) EP2305673A4 (ja)
JP (1) JPWO2010013768A1 (ja)
TW (1) TW201008935A (ja)
WO (1) WO2010013768A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020097595A (ja) * 2014-02-07 2020-06-25 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための新規な塩及びその医薬組成物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201336497A (zh) 2007-02-08 2013-09-16 Daiichi Sankyo Co Ltd 噻唑啶二酮化合物之結晶型及其製法
EP2311834A4 (en) * 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018081A1 (fr) 1997-10-08 1999-04-15 Sankyo Company, Limited Composes heterocycliques condenses substitues
JPH11193276A (ja) * 1997-10-08 1999-07-21 Sankyo Co Ltd 置換縮合複素環化合物
JP2000351769A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd インスリン抵抗性改善剤
JP2000351779A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd アミン誘導体化合物
JP2002179568A (ja) * 2000-10-06 2002-06-26 Sankyo Co Ltd アミン誘導体化合物を含有する糖尿病予防剤、治療剤
WO2003053440A1 (fr) 2001-12-11 2003-07-03 Sankyo Company, Limited Composition medicinale
JP2003238406A (ja) 2001-12-11 2003-08-27 Sankyo Co Ltd 医薬組成物
WO2004000356A1 (ja) 2002-06-25 2003-12-31 Sankyo Company, Limited 利尿剤及びペルオキシソーム増殖因子活性化受容体（PPAR)γ活性化剤を含有する医薬組成物
JP2004083574A (ja) 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
WO2004083167A1 (ja) 2003-03-18 2004-09-30 Sankyo Company Limited スルファミド誘導体及びその医薬組成物
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
WO2006035685A1 (ja) * 2004-09-28 2006-04-06 Sankyo Company, Limited ６－置換－１－メチル－１－ｈ－ベンズイミダゾール誘導体の製造方法及びその製造中間体
WO2007091622A1 (ja) 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物
WO2008099944A1 (en) * 2007-02-08 2008-08-21 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione derivative and its manufacturing method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ300691B6 (cs) * 1999-04-07 2009-07-15 Sankyo Company, Limited Derivát aminu, jeho použití a farmaceutický prostredek jej obsahující

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018081A1 (fr) 1997-10-08 1999-04-15 Sankyo Company, Limited Composes heterocycliques condenses substitues
JPH11193276A (ja) * 1997-10-08 1999-07-21 Sankyo Co Ltd 置換縮合複素環化合物
EP1022272A1 (en) 1997-10-08 2000-07-26 Sankyo Company Limited Substituted fused heterocyclic compounds
US6432993B1 (en) 1997-10-08 2002-08-13 Sankyo Company, Limited Substituted fused heterocyclic compound
JP3488099B2 (ja) 1997-10-08 2004-01-19 三共株式会社 置換縮合複素環化合物
JP2000351769A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd インスリン抵抗性改善剤
JP2000351779A (ja) * 1999-04-07 2000-12-19 Sankyo Co Ltd アミン誘導体化合物
JP2002179568A (ja) * 2000-10-06 2002-06-26 Sankyo Co Ltd アミン誘導体化合物を含有する糖尿病予防剤、治療剤
JP2003238406A (ja) 2001-12-11 2003-08-27 Sankyo Co Ltd 医薬組成物
WO2003053440A1 (fr) 2001-12-11 2003-07-03 Sankyo Company, Limited Composition medicinale
WO2004000356A1 (ja) 2002-06-25 2003-12-31 Sankyo Company, Limited 利尿剤及びペルオキシソーム増殖因子活性化受容体（PPAR)γ活性化剤を含有する医薬組成物
JP2004083574A (ja) 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
WO2004083167A1 (ja) 2003-03-18 2004-09-30 Sankyo Company Limited スルファミド誘導体及びその医薬組成物
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
WO2006035685A1 (ja) * 2004-09-28 2006-04-06 Sankyo Company, Limited ６－置換－１－メチル－１－ｈ－ベンズイミダゾール誘導体の製造方法及びその製造中間体
WO2007091622A1 (ja) 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物
WO2008099944A1 (en) * 2007-02-08 2008-08-21 Daiichi Sankyo Company, Limited Crystalline forms of thiazolidinedione derivative and its manufacturing method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2305673A4

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020097595A (ja) * 2014-02-07 2020-06-25 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための新規な塩及びその医薬組成物
US11667633B2 (en) 2014-02-07 2023-06-06 Galapagos Nv Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP2305673A4 (en) 2011-11-02
US20110124692A1 (en) 2011-05-26
TW201008935A (en) 2010-03-01
EP2305673A1 (en) 2011-04-06
JPWO2010013768A1 (ja) 2012-01-12

Similar Documents

Publication Publication Date Title
MX2009003535A (es) Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas.
NZ600801A (en) Substituted imidazopyridinyl-aminopyridine compounds
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2009068170A3 (de) 2- (benzyl- und 1h- pyrazol-4 -ylmethyl) sulfinyl-thiazol-derivate als herbizide und pflanzenwachstumsregulatoren
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20092314L (no) Benzamidderivater som EP4 receptoragonister
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
NO20085121L (no) Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme
NO20084403L (no) Cykloheksylpyrazol-lactamderivater som inhibitorer av II-beta-hydroksysteroid dehydrogenase I
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
NZ609955A (en) Sgc stimulators
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
NO20085064L (no) 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
WO2008126899A1 (ja) ５員環へテロ環誘導体及びその医薬用途
UY31244A1 (es) Profarmacos dipeptoides y su uso
NO20085067L (no) 4,5-difenyl-pyrimidinyl substituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
CA2725933A1 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
WO2007106879A3 (en) Process for preparing n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide and related metabolites thereof
SG10201407430TA (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
MY163114A (en) Cyclopentylacrylamide derivative
NZ587518A (en) Crystalline form III of (3,5-bis trifluoromethyl)-N-[4-methyl-3-({ 4-(pyridin-3 yl)-pyrimidin-2-yl} amino)-phenyl]-benzamide
NO20090282L (no) Syklopropylaminderivater som histamin H3 reseptormodulatorer
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803010

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010522748

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2009803010

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13056648

Country of ref document: US